IL314213A - Treatment of autoimmune encephalitis with cetralizumab - Google Patents

Treatment of autoimmune encephalitis with cetralizumab

Info

Publication number
IL314213A
IL314213A IL314213A IL31421324A IL314213A IL 314213 A IL314213 A IL 314213A IL 314213 A IL314213 A IL 314213A IL 31421324 A IL31421324 A IL 31421324A IL 314213 A IL314213 A IL 314213A
Authority
IL
Israel
Prior art keywords
satralizumab
treatment
autoimmune encephalitis
encephalitis
autoimmune
Prior art date
Application number
IL314213A
Other languages
English (en)
Hebrew (he)
Original Assignee
Chugai Pharmaceutical Co Ltd
Hoffmann La Roche
Ito Hajime
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Hoffmann La Roche, Ito Hajime, Genentech Inc filed Critical Chugai Pharmaceutical Co Ltd
Publication of IL314213A publication Critical patent/IL314213A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL314213A 2022-01-19 2023-01-18 Treatment of autoimmune encephalitis with cetralizumab IL314213A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263300893P 2022-01-19 2022-01-19
PCT/JP2023/001270 WO2023140269A1 (en) 2022-01-19 2023-01-18 Treatment of autoimmune encephalitis with satralizumab

Publications (1)

Publication Number Publication Date
IL314213A true IL314213A (en) 2024-09-01

Family

ID=87348849

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314213A IL314213A (en) 2022-01-19 2023-01-18 Treatment of autoimmune encephalitis with cetralizumab

Country Status (11)

Country Link
US (1) US20250127891A1 (https=)
EP (1) EP4466018A4 (https=)
JP (1) JP2025502891A (https=)
KR (1) KR20240145472A (https=)
CN (1) CN118900699A (https=)
AU (1) AU2023209259A1 (https=)
CA (1) CA3243067A1 (https=)
IL (1) IL314213A (https=)
MX (1) MX2024008835A (https=)
TW (1) TW202337495A (https=)
WO (1) WO2023140269A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Il-6阻害剤を含有する喘息の治療剤
IL287220B2 (en) 2019-04-17 2026-03-01 Univ Hiroshima A therapeutic agent for urological cancer characterized by administering an IL-6 inhibitor in combination with a CCR2 inhibitor
AU2021278562A1 (en) 2020-05-29 2022-12-01 Chugai Seiyaku Kabushiki Kaisha Antibody-containing formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206775B1 (en) 2007-09-26 2016-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-il-6 receptor antibody
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
US20120039840A1 (en) 2008-12-02 2012-02-16 Hunter Christopher A Use of IL-27-P28 to antagonize IL-6 mediated signaling
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Il−6関連疾患治療用組成物
JPWO2020202839A1 (https=) * 2019-03-29 2020-10-08

Also Published As

Publication number Publication date
TW202337495A (zh) 2023-10-01
EP4466018A4 (en) 2026-03-25
MX2024008835A (es) 2024-07-25
CA3243067A1 (en) 2023-07-27
CN118900699A (zh) 2024-11-05
AU2023209259A1 (en) 2024-07-18
JP2025502891A (ja) 2025-01-28
WO2023140269A1 (en) 2023-07-27
EP4466018A1 (en) 2024-11-27
US20250127891A1 (en) 2025-04-24
KR20240145472A (ko) 2024-10-07

Similar Documents

Publication Publication Date Title
IL314213A (en) Treatment of autoimmune encephalitis with cetralizumab
GB202006665D0 (en) Treatment of ischaemia
IL315503A (en) Treatment methods
IL316804A (en) Treating autoimmune diseases with engineered immune cells
IL291146A (en) Treatment of hidradenitis with jak inhibitors
IL320711A (en) Treatment methods
ES3062709T3 (en) Treatment of t cell lymphoma
SG11202011775VA (en) Antiviral treatment of flavivirus infection
IL276905A (en) Treatment and prevention of preeclampsia
GB202201819D0 (en) Methods of treatment
SMT202400302T1 (it) Trattamento di colangiopatie con seladelpar
IL285743A (en) Diagnosis and treatment of medulloblastoma
IL321175A (en) Treatment methods with tardifitant
GB202001353D0 (en) Treatment of skin conditions
GB202102257D0 (en) Treatment of shells
GB202007037D0 (en) Treatment of ali and ards
GB202315695D0 (en) TReatment of cariomyopathy
GB202212506D0 (en) Treatment of covid-19
IL325944A (en) Treatment methods
GB202307686D0 (en) Treatment of conditions
GB202101251D0 (en) Treatment of conditions
GB202118007D0 (en) Methods of treatment
GB202118011D0 (en) Methods of treatment
GB202118006D0 (en) Methods of treatment
GB202108245D0 (en) Methods of treatment